https://scholars.lib.ntu.edu.tw/handle/123456789/564843
標題: | Synthesis, DNA binding, and cytotoxicity of 1,4-bis(2-amino-ethylamino)anthraquinone-amino acid conjugates | 作者: | LING-WEI HSIN Wang H.-P. Kao P.-H. Lee O. Chen W.-R. Chen H.-W. JIH-HWA GUH Chan Y.-L. His C.-P. Yang M.-S. TSAI-KUN LI Lee C.-H. |
公開日期: | 2008 | 卷: | 16 | 期: | 2 | 起(迄)頁: | 1006-1014 | 來源出版物: | Bioorganic and Medicinal Chemistry | 摘要: | Two series of 1,4-bis(2-amino-ethylamino)anthraquinone-amino acid conjugates (BACs), ametantrone (AT)-amino acid conjugates (AACs) and mitoxantrone (MX)-amino acid conjugates (MACs), were designed and synthesized. The DNA binding of BACs was evaluated by DNA thermal denaturation experiment. In the series, the methionine-substituted BACs had the weakest DNA binding, while the lysine-substituted BACs had the highest Tm values. The abilities of BACs to inhibit the growth of MCF-7, NCI-H460, SF-268, and PC-3 cell lines were determined. l-Met-MAC 16 and l-Lys-MAC 20 were the most potent growth inhibitors. MAC 16 was more cytotoxic than MX, whereas the Tm of MAC 16 was much lower than that of MX. In contrast to MAC 16, l-Lys-MAC 20 demonstrated higher Tm than MX. These data suggested that Met-BACs possessed a different pharmacological profile, in which the ability to stabilize DNA is not parallel to the ability to kill cancer cells, from that of AT and MX. The primary mechanism of cytotoxicity for MAC 16 was most likely through TOP2 poisoning. Therefore, MAC 16 may provide a lead for the development of novel generations of anthraquinone-type antitumor agents. ? 2007 Elsevier Ltd. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-38549094229&doi=10.1016%2fj.bmc.2007.10.012&partnerID=40&md5=2db213e0aa90eb068cc480e0c82a289f https://scholars.lib.ntu.edu.tw/handle/123456789/564843 |
ISSN: | 9680896 | DOI: | 10.1016/j.bmc.2007.10.012 | SDG/關鍵字: | 1,4 bis[2 (2 amino 3 hydroxy propionylamino)ethylamino] 9,10 anthracenedione trifluoroacetate; 1,4 bis[2 (2 amino 3 tert butoxypropionylamino)ethylamino] 9,10 anthracenedione; 1,4 bis[2 (2 amino 4 methylsulfanyl butyrylamino)ethylamino] 9,10 anthracenedione trifluoroacetate; 1,4 bis[2 (2 amino 4 methylsulfanylbutyrylamino)ethylamino] 5,8 dihydroxy 9,10 anthracenedione trifluoroacetate; 1,4 bis[2 (2 amino 4 methylsulfanylbutyrylamino)ethylamino] 5,8 dihyroxy 9,10 anthracenedione trifluoroacetate; 1,4 bis[2 (2 amino 6 tert butoxycarbonylamino hexanoylamino) ethylamino] 9,10 anthracenedione; 1,4 bis[2 (2 tert butoxycarbonylamino 4 methylsulfanyl butyrylamino)ethylamino] 9,10 anthracenedione; 1,4 bis[2 (2 tert butoxycarbonylamino 4 methylsulfanylbutyrylamino)ethylamino] 5,8 dihydroxy 9,10 anthracenedione; 1,4 bis[2 (2,6 diamino hexanoylamino)ethylamino] 5,8 dihydroxy 9,10 anthracenedione trifluoroacetate; 1,4 bis[2 (2,6 diamino hexanoylamino)ethylamino] 9,10 anthracenedione; 1,4 bis[2 (2,6 diaminohexanoyl carbamoyl)ethylamino] 9,10 anthracenedione; 1,4 bis[2 [2 amino 3 (4 hydroxyphenyl)propionylamino]ethylamino] 9,10 anthracenedione trifluoroacetate; 1,4 bis[2 [2 amino 3 (4 tert butoxyphenyl)propionylamino]ethylamino] 9,10 anthracenedione trifluoroacetate; 1,4 bis[2 [2,6 bis(tert butoxycarbonylamino)hexanoylamino]ethylamino] 5,8 dihydroxy 9,10 anthracenedione; 1,4 bis[2 [2,6 bis(tert butoxycarbonylamino)hexanoylamino]ethylamino] 9,10 anthracenedione; 1,4 bis[2 [3 tert butoxy 2 (9h fluoren 9 yl methoxycarbonylamino) propionylamino]ethylamino] 9,10 anthracenedione; 1,4 bis[2 [6 tert butoxycarbonylamino 2 (9h fluoren 9 ylmethoxycarbonylamino)hexanoylamino]ethylamino] 9,10 anthracenedione; ametantrone; antineoplastic agent; DNA; lysine; methionine; mitoxantrone; unclassified drug; article; cancer cell; cancer growth; cancer inhibition; cell killing; cytotoxicity; DNA binding; DNA denaturation; drug design; drug potency; drug synthesis; human; human cell; Amino Acid Sequence; Amino Acids; Anthraquinones; Antineoplastic Agents; Combinatorial Chemistry Techniques; DNA; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Stereoisomerism; Structure-Activity Relationship |
顯示於: | 藥學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。